Evolving Therapeutic Strategies in Cancer Therapy–Induced Bone Loss: The Pharmacist's Role in Minimizing Fractures

Rick Miller, PharmD, BCPS, BCOP, and Gerard Mascara, PharmD
Published Online: Wednesday, August 22, 2012
Follow Pharmacy_Times:
This activity is supported by an educational donation provided by Amgen.

Evolving Therapeutic Strategies in Cancer Therapy–Induced Bone Loss: The Pharmacist's Role in Minimizing Fractures

 
Rick Miller, PharmD, BCPS, BCOP

Allegheny General Hospital
Department of Pharmacy Services
Clinical Adjunct Faculty
University of Pittsburgh
Duquesne University
Pittsburgh, PA

 
Gerard Mascara, PharmD

PGY2 Hematology/Oncology Pharmacy
Resident
Allegheny General Hospital
Pittsburgh, PA

 

 
Rick Miller, PharmD, BCPS, BCOP, and Gerard Mascara, PharmD, have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.
 
Pharmacy Times Office of Continuing Professional Education Planning Staff
 
Judy V. Lum, MPA, Ann C. Lichti, CCMEP, and Elena Beyzarov, PharmD, have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.
 
Pharmacy Times Editorial Staff
 
Jennifer Whartenby and David Allikas have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.
 
The peer reviewer of this activity has no relevant financial relationships with commercial interests to disclose related to this activity.
 

 
Educational Objectives

Upon completion of this educational activity, participants should be able to:
  1. Examine the physiology and biochemical mechanisms associated with general bone health, normal bone loss, and bone loss due to secondary causes, particularly cancer therapy–induced bone loss (CTIBL).
  2. Identify patients at risk for CTIBL and subsequent fractures, and recommend bone mineral density testing and/or physician referral in an effort to minimize burden of fractures.
  3. Recommend appropriate nonpharmacologic and pharmacologic interventions for management of CTIBL and ensure follow-up monitoring.
  4. Formulate counseling strategies regarding prevention and management of CITBL including lifestyle modification and medication adherence.
 
Target audience: Pharmacists
Type of activity: Knowledge
Release date: August 10, 2012
Expiration date: August 10, 2014
Estimated time to complete activity: 2 hours
Fee: This lesson is free online
 
Click here to view this activity.

Related Articles
Olaparib treats women with advanced ovarian cancer associated with defective BRCA genes.
Priced at approximately $178,000 for 2 courses of treatment, Blincyto will be one of the most expensive cancer medications on the market.
The FDA today approved a new indication for ramucirumab for the treatment of metastatic non-small cell lung cancer.
Merck’s anti–PD-1 therapy Keytruda has demonstrated an overall response rate of 18.5% among patients with PD-L1 positive, advanced triple-negative breast cancer, one of the most aggressive forms of breast cancer.
Latest Issues
$auto_registration$